Artivion(AORT)

Focus: Artivion is a publicly traded medical device and tissue engineering company focused on cardiovascular surgical solutions, including mechanical valves, cryopreserved tissues, and hemostatic devices. With $354M in FY2025 revenue and 1,001–5,000 employees, it operates as a specialized player in the cardiac surgery market.

Cardiovascular

Profile data last refreshed 3h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1001-5000

Open Jobs

About Artivion

AI assessmentNot Hiring

No open roles listed right now. Follow Artivion to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$354M

Key Products

On-X Aortic Mechanical Valve

Aortic Valve Disease

Growth

Lead Phase 3 program with active trial enrollment; represents primary near-term catalyst for the company.

Pipeline & Clinical Trials

Help build intelligence for Artivion

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established public company with $354M revenue and 40+ year track record in cardiovascular devices, offering stability and brand recognition
Focused portfolio in high-acuity cardiac surgery with multiple clinical-stage programs (On-X Aortic Valve in Phase 3) provides clear career visibility in specialized therapeutics
Direct involvement in unmet surgical needs (acute aortic dissection, mitral regurgitation, aortic valve disease) appeals to mission-driven professionals

Watch Out For

Modest R&D intensity at 8% ($29M spend on $354M revenue) and declining R&D investment year-over-year ($39M in FY2024) signals constrained innovation capacity and limited research role growth
Persistent net losses ($30.7M in FY2025, $19.2M in FY2024) despite revenue growth, coupled with declining cash position ($53M, down from $59M), raise sustainability concerns and restructuring risk
Zero active job openings at time of data collection and no evidence of H1B sponsorship suggest limited hiring momentum and potential visa sponsorship constraints

Generated by Claude from Artivion's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Arcevo LSA

Aortic Arch Aneurysm

N/A

Clinical Trials (1)

NCT07089576Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA

N/A

PhotoFix

Vascular Diseases

N/A

Clinical Trials (2)

NCT03669042Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vascular Surgery

N/A

NCT05314868Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium in Cardiac Repair or Reconstruction Surgery

N/A

PerClot Polysaccharide Hemostatic System

Blood Loss, Surgical

N/A

Clinical Trials (1)

NCT02359994Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System

N/A

AMDS

Acute Aortic Dissection

N/A

Clinical Trials (2)

NCT03035643DARTS I Feasibility Study

N/A

NCT03397251DARTS I: Feasibility, Safety, and Performance Trial

N/A

Chord-X

Mitral Regurgitation

N/A

Clinical Trials (1)

NCT07413926Mitral Valve Repair With the Chord-X System: A Long Term Evaluation

N/A

Cryopreserved Saphenous Vein Allograft

Critical Limb Ischemia

N/A

Clinical Trials (1)

NCT01799811Cryopreserved Saphenous Vein Allograft in Patients With Critical Limb Ischemia for Peripheral Revascularization

N/A

On-X Aortic Mechanical Valve

Aortic Valve Disease

Phase 3

Clinical Trials (1)

NCT04142658PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 1984

Portfolio: 9 clinical trials

Top TAs: Cardiovascular, Nephrology

SEC Filings: 2 available

Therapeutic Area Focus

Cardiovascular

5 pipeline

Nephrology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$354M13%

R&D Spend

$29M(8%)26%

Net Income

-$31M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 3 crawl cycles

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo